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Introduction
Ischemic stroke (IS) is one of the leading causes of mor-
tality and disability worldwide, with an important increase 
in low-middle income countries for the last 20 years [1]. 
Moreover, stroke has the tendency to affect younger people 
in the less developed countries with consecutive impact on 
economic and social levels. There are numerous targets to 
improve in the management of ischemic stroke, starting 
with the population awareness about stroke and emergency 
service priority for such patients, continuing with the neces-
sity of comprehensive stroke centres for acute/24h diagnosis 
and acute treatment, and finishing with appropriate long-
term rehabilitation centres for in- and outpatients [2].
Given the limited therapeutic options for the acute isch-
emic stroke patients – chemical and mechanical throm-
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Abstract
Background: Ischemic stroke is one of the leading causes of mortality and disability worldwide. Numerous studies were performed to assess the risk of 
clinical deterioration of acute ischemic stroke patients, including the risk of haemorrhagic transformation. The complexity of cerebral ischemia pathology 
raised the possibility of a multitude of candidate-molecules to be studied as stroke biomarkers. The blood brain barrier integrity biomarkers have shown 
promising results both in fundamental and clinical studies. Matrix metalloproteinases have been extensively analysed and gave encouraging results for 
predicting unfavourable neurological outcome, including the risk for haemorrhagic transformation. Matrix metalloproteinase-9 plays a crucial role in 
the disruption of the blood-brain barrier following focal cerebral ischemic stroke. Elevated matrix metalloproteinase-2 levels are responsible for the 
degradation of tight junction proteins, basal lamina and neuronal injury after ischemia, and may contribute to infarction and hemorrhagic volume. The 
review provides an overview of matrix metalloproteinases’ role in the prognosis of acute ischemic stroke patients, regarding the stroke outcome and the 
risk of haemorrhagic transformation. 
Conclusions: Matrix metalloproteinases, especially gelatinases, are extensively studied for their predictive value in ischemic stroke evolution. Matrix 
metalloproteinase-2 and matrix metalloproteinase-9 correlate with stroke severity and haemorrhagic transformation in acute ischemic stroke, but large 
validation studies are needed for practical translation. Future studies should focus on developing a biomarker panel for predicting outcomes in stroke 
patients.
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time-window, only one in five patients (according to inter-
national data) or even less – one in ten patients (according 
to national data, in hospitals with stoke units), will receive 
specific treatment for cerebral ischemia [3]. These little en-
couraging data can become even worse when regarding the 
possible complications of thrombolysis, including haemor-
rhagic transformation (HT) [3-7]. HT of ischemic stroke 
represents the bleeding in the infarcted area of the brain af-
ter IS. It can occur in up to 70% of cases of cerebral ischemia 
– by radiologic and morphologic studies, with a various per-
centage of symptomatic HT (HT associated with worsening 
of the neurological status) – from 1 to 20% [8]. 
Numerous studies were performed to assess the risk of 
clinical deterioration of acute IS patients, including the risk 
of HT [9]. Various parameters were analysed, including clin-
ical manifestations, radiologic features, laboratory factors, 
in a separate way, either in combined tools – scores [10-12]. 
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Given the acute onset of cerebral ischemia and the limited 
time for diagnosis, a high percentage of the researches fo-
cused on finding the “gold-molecule” able to identify and/
or predict the evolution of patients with IS, similar to the 
cardiac troponins – so-called cerebral infarction biomarker 
[13]. Biomarkers are considered “signatures” of different bi-
ological processes, able to identify, stratify, predict the evo-
lution of the assessed events.
The complexity of cerebral ischemia pathology raised 
the possibility of a multitude of candidate-molecules to be 
studied as stroke biomarkers. A PubMed search of stroke 
and biomarkers key words reveals an important number of 
studies and publications in the field (more than 15 thou-
sand), starting with 1 article in the 80-s to up to 1662 pa-
pers in 2020. The studied molecules can be classified by the 
target process in the stroke pathology, but also, even more 
important for clinical activity, by the potential use of the 
biomarker.  
The classification according to the affected pathway in 
the IS pathogenesis includes molecules related to: inflam-
mation/oxidative stress, vasoreactivity, coagulation/ fibri-
nolysis disorders, and to the brain-blood barrier (BBB) dis-
ruption. The potential clinical use of the stroke biomarkers 
includes the following categories: prediction of stroke risk, 
determination of stroke mechanisms, diagnosis of cerebral 
vein thrombosis, prediction of infarct volume, prediction 
of stroke outcome, estimation of in-hospital complications 
risk, determination of the response to therapy [13, 14]. 
Regarding the response to therapy and stroke outcome, 
the BBB integrity biomarkers have shown promising results 
both in fundamental and clinical studies. Among them, ma-
trix metalloproteinases (MMPs) have been extensively anal-
ysed and gave good results both for predicting the answer to 
treatment, and also for unfavourable neurological outcome, 
including the risk for haemorrhagic transformation [13].
The aim of this research was the review of matrix me-
talloproteinases’ role in the prognosis of acute ischemic 
stroke patients, regarding the stroke outcome and the risk of 
haemorrhagic transformation. 
Material and methods
The online research using the PubMed database has 
been conducted. There have been used the MeSh terms: 
cerebrovascular accident and matrix metalloproteinases, 
obtaining the initial number of 1425 articles for the com-
bined searched terms (1995-2021). To restrain the number 
of the studies, there have been applied the following filters: 
duration – articles published within the last 10 years (2011-
2021), species – studies performed on humans, and type of 
the study – clinical study, clinical trial, review, systematic 
review, and meta-analysis. The reasoning for the applied fil-
ters was to reveal the most recent researches, with the high-
est clinical application and feasibility. The selection revealed 
130 articles. Individual analysis of the articles titles was 
thereafter done, with consecutive exclusion of the articles 
focusing on other cerebrovascular pathologies (e.g. cerebral 
sinuses thrombosis, subarachnoid haemorrhage), articles in 
other languages than English, studies of the different diag-
nosis tools (e.g. laboratory devices). For the remaining 96 
articles, abstracts were processed, with final selection of 26 
articles for full text analysis (fig. 1).
Nine supplementary articles on complementary data 
for our research – stroke epidemiological data, blood-brain 
barrier structure – were included.
Results and discussion
The sudden blockage of a cerebral vessel leads to imme-
diate and delayed pathological processes linked with oxygen 
and glucose delivery failure – a cascade of ischemia-induced 
pathological events, that ultimately lead to irreversible neu-
ronal injury – neuronal death [7, 15]. At each stage of the 
IS pathogenesis, numerous molecules are involved with se-
quential plasma increase/decrease, making them potential 
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Fig. 1.  Algorithm of literature research 
 
Nine supplementary articles on complementary data for our research – stroke epidemiological 
data, blood-brain barrier structure – were included. 
MeSh terms cerebrovascular accident and matrix metalloproteinases 
(1995-2021). 
Filters: duration – articles published for the last 10 (2011-2021) 
years, species – studies performed on humans, and type of the study – 
clinical study, clinical trial, review, systematic review, and meta-
analysis. 
Analysis of the articles titles. 
Processing of the abstracts. 
Fig. 1.  Algorithm of literature research
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biomarkers for stroke. As biomarkers, the molecules should 
be easily measurable, specific and sensitive [16].
Emphasising the most important steps in the cerebral 
ischemia, the acute energy failure caused by vessels block-
age will determine at first a burst of excitotoxicity (by acti-
vation of N-methyl-aspartate receptors and calcium chan-
nels), which leads to the activation of inflammatory re-
sponse (synthesis of pro-inflammatory cytokines as tumor 
necrosis factor α (TNF-α), interleukine 1β (IL-1β), activa-
tion of neural nitric oxide (NO) synthase, reactive oxygen 
species synthesis, oedema and finally neurons death (apop-
tosis). TNF-α and IL-1β synthesis will trigger a second line 
cytokine expression with release of interleukine (IL-6) and 
chemokine CXCL-8. These pro-inflammatory agents can 
increase the C-reactive protein level and start the expression 
of numerous matrix metalloproteinases [1, 16, 17].
Matrix metalloproteinases are a family of zinc-depen-
dent endoproteases with multiple roles in tissue remodelling 
and degradation of various proteins in the extracellular ma-
trix (ECM): collagen, proteoglycans, elastin or fibronectin. 
MMPs promote inflammatory response, cell proliferation, 
migration, and differentiation. Among MMPs, gelatinases 
(MMP-2 and MMP-9) are the most investigated enzymes, 
given the high prevalence and widespread distribution in 
different tissues (e.g. endothelium, intima, vascular adven-
titia, fibroblasts, platelets, macrophages, neutrophils, brain, 
heart, lungs, liver, kidney, breast, uterus, placenta, ovary, 
testis, prostate, tooth enamel, skin, keratinocytes) [16]. 
Therefore, MMP-2 and MMP-9 are studied in various medi-
cal fields. In neurology, gelatinases were investigated related 
to stroke, multiple sclerosis, Alzheimer disease, Parkinson 
disease, neuroinfections, brain tumors and others [16-18].
Characteristics of matrix metalloproteinases
In the early 1960s, MMPs were first identified by Gross 
and Lapiere as enzymes with collagen proteolytic activity 
that causes extra-cellular matrix protein degradation during 
resorption of the tadpole tail [5,13]. MMPs are calcium-de-
pendent zinc-endopeptidases, which are expressed as inac-
tive zymogens with a pro-peptide domain (pro-MMPs) that 
must be removed for MMP activation [18-20].
At present, time, in vertebrates, there are 28 members in 
the MMP family, at least 23 are expressed in human tissues 
[6, 21], and 14 of those – in the blood vessels. Based on the 
variations in MMPs biochemical structure and affinity to 
substrates, they were classified into several groups including 
[16, 17]:
1. Collagenases (MMP-1, MMP-8, MMP-13, MMP-18),
2. Gelatinases (MMP-2, MMP-9),
3. Stromelysins (MMP-3, MMP-10, MMP-11),
4. Matrilysins (MMP-7, MMP-26),
5. Membrane-type matrix metalloproteinases (MMP-14, 
MMP-15, MMp-16, MMP-17, MMP-24, MMP-25),
6. Other MMPs (MMP-12, MMP-19, MMP-20, MMP-
21, MMP-23, MMP-27, MMP-28). 
The majority of MMPs are produced and secreted from 
cells in the inactive form (proenzymes) with consecutive ac-
tivation in the final active form within the extracellular ma-
trix [16]. After activation, their activity is regulated mainly 
by natural tissue inhibitors of MMPs (TIMPs) that can bind 
to the active side and block the substrate availability. To 
date, four types of tissue inhibitors of MMPs are known, 
numbered from 1 to 4. Each TIMP can inhibit multiple 
MMPs with different efficacies [16, 17, 20]. Among four 
known TIMPs, TIMP-1 has the highest affinity to MMP-9, 
and TIMP-2 for MMP-2 [1, 22].
 The role of gelatinases in the progress of IS
The plasma concentration of gelatinases varies during 
IS, both in the acute and later phases of cerebral ischemia 
[1, 16].
The concentration of MMP-9 is elevated in serum dur-
ing acute phase of all types of ISs, starting from 12h up to 
48h after stroke onset, and are increasingly correlated with 
neurological deterioration [23]. Among stroke patients, the 
cardioembolic stroke results in the highest MMP-2 concen-
trations compared to other types of stroke [16]. 
MMP-9 could have a prognosis value for ischemic 
stroke occurrence, as shown by a recent study conducted 
on patients with attrial fibrilation [24].  From 268 unique 
biomarkers, only 6 were most strongly associated with sub-
sequent ischemic stroke/systemic embolism, among them 
matrix metalloproteinase-9.
The following main functions/processes are influenced 
by gelatinases activity during IS [16, 17, 21, 25, 26]: 
1. Brain-blood-barrier (BBB) destruction – in addition 
to cleavage of collagen type IV, MMP-9 is able to digest oc-
cludin and claudin – essential components of tight junc-
tion proteins (TJPs) in the BBB. Finally, the high activity of 
MMP-9 in the blood within the acute phase of IS increases 
the risk of secondary bleeding within the ischemic focus. 
Moreover, the appearance of active enzyme form in plasma, 
as a result of rtPA administration, augments the risk of in-
tracranial bleeding. 
2. Inflammatory answer – TNF-α and IL-6 can activate 
the expression of MMP-9 which is involved into further ac-
tivation of IL-1β and CXCL-8. 
3. Formation of glial scar – mechanism of the second 
gelatinase, MMP-2. 
MMP-9 plays a crucial role in the disruption of the BBB 
following focal cerebral ischemic stroke. Elevated MMP-2 
levels were responsible for the degradation of tight junction 
proteins, basal lamina and neuronal injury after ischemia, 
and may contribute to infarction and hemorrhagic volume 
[1, 15, 27].  MMP-2 deficiency reduced the incidence of 
hemorrhage in the cortex in mouse [6]. Fundamental stud-
ies on mice with early reperfusion suggested that MMP-2 
deficiency as well as MMP-2 and MMP-9 double deficiency 
were more protective than MMP-9 deficiency alone against 
HT after the early stages of ischemia and reperfusion [1].
The pro-inflammatory action of the MMPs have been 
shown to correlate with the atherosclerotic plaques rupture, 
and therefore responsible for cardio- and cerebrovascular 
events. Given the MMP-2 action substrate (structural com-
ponents of the sub-endothelium of medium and large-size 
arteries, like gelatin, fibronectin, laminin-1, type IV colla-
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gen and elastin), its role in vascular remodeling, neutrophil 
and platelet activation, numerous studies have been con-
ducted to analyze the borderline between physiologic and 
pathologic hemostatic answer at the levels of atherosclerotic 
plaques promoted by these enzymes [28]. For example, Lenti 
M. et al. have demonstrated that atherosclerotic plaques of 
patients undergoing carotid endarterectomy determine 
platelet activation due to their high content in active MMP-
2, the effect being confirmed by abolishment after preincu-
bation of platelets with MMP-2 inhibitors [28]. 
gelatinases and HT 
HT can occur in the natural evolution of ischemic stroke, 
but more frequently is a complication of rt-PA thrombolysis 
in the treatment of acute ischemic stroke. 
Radiologically, HT is defined and divided into 4 sub-
types: small petechial hemorrhagic infarction (HI1), con-
fluent petechial hemorrhagic infarction (HI2), small pa-
renchymal hemorrhage (PH1, < 30% of infarct, mild mass 
effect), and large parenchymal hemorrhage (PH2, > 30% of 
infarct, marked mass effect) [29].  Clinically, HT is divided 
in: asymptomatic HT (no clinical worsening on the National 
Institutes of Health Stroke Scale (NIHSS) score despite 
HTs), minor symptomatic HT (a 1 to 3-point increase in 
the NIHSS score), and major symptomatic HT (a ≥ 4-point 
increase in the NIHSS score) [29]. Despite the “asymptom-
atic” term, long-term prognosis is poorer in ischemic stroke 
patients with all clinical types of HT. 
Structurally, HT of IS occurs when blood-brain barrier 
is disrupted. The BBB separates the brain parenchyma and 
the blood circulation, providing anatomical and physiologi-
cal protection for the central nervous system, supplying 
nutrition for brain tissue, filtering harmful substances from 
the brain back to the blood and protecting the brain from 
toxic material in the blood [25, 29].
The rupture of BBB damages the whole neurovascular 
unit (NVU), which consists of the extracellular matrix, en-
dothelial cells, astrocytes, neurons, and pericytes [5, 21, 29]. 
The main mechanisms of HT are considered related to pro-
teolysis, oxidative stress and leukocyte infiltration.
HT can occur spontaneously, especially in case of cere-
bral embolism, either induced by anticoagulants, throm-
bolytic therapy and endovascular procedures [23, 30]. All 
these situations are associated with an increased degrada-
tion of the extracellular matrix components by proteolytic 
enzymes, particularly MMPs, which aggravates brain ede-
ma and enhances brain damage.
Different studies applied MMP-9/TIMP-1 ratio as an in-
dicator of MMP-9 activity in vivo. The proteolytic activation 
of MMP-9 is conducted by active forms of other metalopro-
teinases as MMP-2 or MMP-3. The activation of MMP-9 fa-
cilitates the BBB destruction and secondary bleeding within 
the ischemic focus [22, 31]. MMP-2 and MMP-9 have dif-
ferent temporal expression and action in the post-stroke pe-
riod. It was established that MMP-2 is involved in the initial 
phase of BBB opening (maximum at 3h), while MMP-9 is 
more active in the delayed opening of the BBB after isch-
emic stroke [6]. 
Given the higher incidence of HT after thrombolytic 
treatment with rt-PA, numerous fundamental studies were 
conducted to elucidate the mechanisms underlying this 
phenomenon. Thus, it was established that when NVU is 
impaired, rt-PA may cross the brain and activate endog-
enous tPA signaling pathways associated with HT. t-PA 
mostly affects the BBB through various plasminogen inde-
pendent mechanisms, such as the overexpression of MMP-
2, -3 and -9 and activation/cleavage of lipoprotein receptor 
related protein or platelet-derived growth factor receptor 
alpha [15, 29].
Both fundamental and clinical studies have found an el-
evation of gelatinases MMP-2 and MMP-9 in the ischemic 
brain/plasma of IS patients within the first 24h, correlating 
with cerebral infarction extension, worse outcome and HT. 
Preclinical studies demonstrated that MMP-2 plays a key 
role in the initial opening of the BBB after cerebral ischemia 
by degradation of tight junction proteins, collagen, and oc-
cludin. According to literature data, the most extensively 
studied gelatinase in relation to IS and HT, MMP-9 can 
serve as independent predictor of HT after tPA administra-
tion [5, 22]. 
A systematic review (Ramos-Fernandez M. et al., 2011) 
analyzed 22 clinical studies, including 3289 patients, to 
evaluate the role of MMP-9 plasma level in acute ischemic 
stroke. According to this analysis, plasma MMP-9 level, 
measured before the administration of thrombolytic thera-
py in acute stroke patients, accurately predicts the develop-
ment of hemorrhage [32].
Importantly, an analysis of non-selected series of pa-
tients has shown that an MMP-9 value ≥140 ng/mL within 
24h of stroke onset had a high negative predictive value for 
future HT.  The data suggest that a lower plasma level of 
MMP-9 is associated with a low risk of HT [23, 32, 33]. 
Experimental studies strengthen the correlation of both 
MMP-2 and MMP-9 with HT, with even a higher associa-
tion of MMP-2 with HT, given its action mechanism by 
degradation of tight-junction proteins and the basal lamina, 
BBB disruption and neuronal injury [23].
The fundamental studies raised the idea of MMPs in-
hibition for improving clinical outcome of IS patients. 
Numerous molecules have been analyzed in clinical settings 
to inhibit gelatinases, including minocycline, (4-phenoxy-
phenylsulfonyl) methylthiirane (known as SB-3CT), lenti-
viral-mediated MMP-9 gene silencing, recombinant TIMP-
1 in its native form, PLGA (poly lactic-co-glycolic acid) 
nanoparticles [5], majority of them showing that inhibition 
of MMP-9 could be a therapeutic strategy for acute isch-
emic stroke treatment, but with a limited time-window after 
which MMP inhibitors have negative impacts on stroke pa-
tients  [6, 12].
Stroke severity and functional outcome versus MMPs 
levels
Stroke severity and final infarct volume are among the 
most important factors associated with functional outcomes 
in patients after IS. The most available and widely used tools 
are those clinical – NIHSS score and radiological – CT and 
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MRI protocols and scores. While their sensibility and speci-
ficity are high, not all hospitals, especially from rural areas, 
have 24h available radiological service. Therefore, the use of 
blood biomarkers to predict stroke patient’s evolution could 
be a good supplement for the clinical assessment and treat-
ment rationale in these cases.
Different biomarkers show good correlation with stroke 
clinical severity and infarct size, and may be useful for pre-
dicting poorer outcomes [23, 31, 32, 34].
In a review on MMPs’ role in BBB breakdown during 
acute ischemic stroke, Lakhan S. et al., 2013, have deter-
mined that cerebral infarct size is reduced in mice deficient 
in MMP-9 or after treatment with MMP inhibitor [1].  
MMP-2/-9 levels, when collected within 20h of stroke 
onset, showed a direct, significant correlation with both ini-
tial and final stroke severity, as measured by the NIHSS and 
infarct size. When collected earlier (within 6h of stroke on-
set), MMP-9 was the only predictor of infarct volume mea-
sured as a diffusion lesion [1, 23].
Consecutively, in an Italian study [31], including 327 
tPA-treated patients, MMP-9 circulating level variation 
proved association, independent of major clinical deter-
minants, with symptomatic HT or death. The MMP-9 se-
rum levels correlated with the NIHSS values prior and after 
thrombolytic treatment. 
In an extensive review by Turner R. et al., 2016, the 
authors highlithed that, in terms of long-term outcomes, 
MMP-9 was associated with a poor neurological outcome 
at 3 months post-stroke and hyperacute levels of MMP-9 
correlated with worse Rankin outcome at 3 months post-
stroke. The review mentions one single study to report that 
both MMP-2 and MMP-9 levels correlated with clinical se-
verity and the extent of the infarct [21].
Iemolo F. et al., 2016, realized a prospective evalu-
ation of a panel of blood biomarkers to assess their value 
in acute stroke prognosis. The panel included the fol-
lowing molecules: Brain Natriuretic Peptide, D-Dimers, 
Matrix-Metalloproteinase-9, and S100β protein generating 
a Multimarker index of these values. The outcome of the 
study was 120-day mortality. Among 244 patients included 
in the analysis, 161 (66.0 %) had an increase of biomark-
ers [34]. However, detailed statistical analysis failed to give 
significant correlations. The authors concluded that neither 
one marker nor combination of all markers was of signifi-
cant benefit in acute stroke diagnostics, and DWI-MRI was 
the procedure with the highest diagnostic quality in case of 
acute cerebral ischemia.
Another study was conducted by Zhong et al., 2017, to 
prospectively investigate the association between serum 
MMP-9 levels and prognosis in patients with acute ischemic 
stroke using data from the China Antihypertensive Trial in 
Acute Ischemic Stroke (CATIS). This large study included 
3.186 participants (2.008 men and 1.178 women). Study 
outcome data on death, major disability (modified Rankin 
Scale score ≥3), and vascular disease were collected at 3 
months after stroke onset. The authors observed dose-re-
sponse associations between higher MMP-9 levels in acute 
ischemic stroke and increased risk of major disability and 
death at 3 months after stroke onset, after adjustment for 
other established covariates  [35].
Conclusions
It has been detected that the involvement of gelati-
nases into multiple physiological and pathological pro-
cesses makes them an attractive target for investigations. 
Numerous researches revealed that both enzymes, MMP-2 
and MMP-9 have their specific role during brain ischemia. 
Promising results are shown by both fundamental and clini-
cal studies analyzing the predictive value for hemorrhagic 
transformation of gelatinases. Thus, MMP-2 and MMP-9 
correlate with stroke severity and haemorrhagic transfor-
mation in acute ischemic stroke, but large validation studies 
for practical translation are needed. 
Given the etiological heterogeneity of ischemic strokes, 
the variety of clinical manifestations, it is challenging to 
identify one single predictive biomarker for stroke outcome. 
Future studies should focus on developing a biomarker pan-
el for predicting outcomes in stroke patients presenting with 
cerebrovascular accident.
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